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Aspergillosis is well known as an infectious complication that
generally occurs in immunocompromised or strongly debilitated
patients and carries a dreadful prognosis.1,2 We read with
interest the results of the large-scale epidemiologic study by
Tong et al. on the economic impact of aspergillosis.3 Aspergil-
losis was associated with a dramatic economic burden. Overall
the length of hospitalization was 7.9 vs. 17.7 days, and the mean
total hospital charge was approximately $44 000 vs. $97 000 in
non-aspergillosis and aspergillosis patients, respectively. The
study was based on two large databases. The Nationwide
Inpatient Sample, developed for the Healthcare Cost and
Utilization Project, and the Medicare Provider Analysis and
Review ﬁle, acquired from the Centers for Medicare and
Medicaid Services.
The databases allowed searching for aspergillosis as an
admission or discharge diagnosis and permitted stratiﬁcation on
diagnosis-related groups (DRGs). The databases, however, did not
allow for more detailed matching or adjustment for disease
severity. Irrespective of underlying pathology (or DRG), severe
infections, such as invasive fungal infections, generally occur in
patients with a high index of disease severity and acute illness.4–6
Greater morbidity results in prolonged hospitalization and
consequently boosts the total hospital charges.7 Accordingly,
these patients were predestined to have higher hospital costs, even
before the development of aspergillosis. As such, the results
obtained from the study by Tong et al. do not reﬂect a fair economic
impact of aspergillosis, since case-patients were not compared
with equally sick control subjects within the same DRG. Ideally,
patients with aspergillosis should be carefully matched for
confounding covariates such as DRG, disease severity, and
exposure time.8,9
We performed a matched cohort study in a subset of patients
with intensive care unit (ICU)-acquired aspergillosis.10 Cases were
matched with controls based on the principle diagnosis, disease
severity as assessed by the acute physiology and chronic health
evaluation (APACHE) II score, and exposure time (length of stay in
the ICU before onset of invasive aspergillosis). Case-patients
experienced a higher resource utilization in terms of necessity for
renal replacement therapy (43% vs. 21%), prolonged ICU stay (24 vs.
12 days), and an extended period of ventilator dependency (21 vs.
9 days). These results are important, since, in particular, extra days
in the ICUwhile beingmechanically ventilated are to be considered
as ‘high-cost-days’. As such, our data add to the report by Tong
et al.–after careful matching for diagnostic category, disease
severity and exposure time, aspergillosis signiﬁcantly increases
healthcare costs.1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.06.014Acknowledgments
S. Blot is supported by a Grant from the European Society of
Intensive Care Medicine and iMDsoft (ECCRN - iMDsoft Patient
Safety Research Award 2008). These sponsors had no speciﬁc role
in the preparation of the manuscript.
Conﬂict of interest: No conﬂict of interest to declare.
References
1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781–803. quiz
804-5.
2. Vandewoude K, Vogelaers D, Blot S. Aspergillosis in the ICU—the new 21st
century problem. Med Mycol 2006;44:S71–6.
3. Tong KB, Lau CJ, Murtagh K, Layton AJ, Seifeldin R. The economic impact of
aspergillosis: analysis of hospital expenditures across patient subgroups. Int J
Infect Dis 2009;13:24–36.
4. Blot S, Vandewoude K. Management of invasive candidiasis in critically ill
patients. Drugs 2004;64:2159–75.
5. Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F. Invasive
aspergillosis in critically ill patients: analysis of risk factors for acquisition and
mortality. Acta Clin Belg 2004;59:251–7.
6. Vandewoude KH, Blot SI, Depuydt P, Benoit D, TemmermanW, Colardyn F, et al.
Clinical relevance of Aspergillus isolation from respiratory tract samples in
critically ill patients. Crit Care 2006;10:R31.
7. Vandijck D, Blot S, Labeau S, Buyle FM, Depaemelaere M, Vandewoude K, et al.
Candidemia in critically ill patients: an analysis of daily antifungal therapy
related costs. J Mycol Med 2008;18:96–9.
8. Blot S, De Bacquer D, Hoste E, Depuydt P, Vandewoude K, De Waele J, et al.
Inﬂuence of matching for exposure time on estimates of attributable mortality
caused by nosocomial bacteremia in critically ill patients. Infect Control Hosp
Epidemiol 2005;26:352–6.
9. Blot S, Depuydt P, Vandewoude K, De Bacquer D. Measuring the impact of
multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007;20:
391–6.
10. Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive
aspergillosis in critically ill patients: attributable mortality and excesses
in length of ICU stay and ventilator dependence. J Hosp Infect 2004;56:
269–76.
Stijn Blota,b,c,*
Anne Pietted
Dominique Vandijckb,e
Christelle Lizyb
Koenraad Vandewoudea,b,
Dirk Vogelaersa,b,c,
aGeneral Internal Medicine & Infectious Diseases,
Ghent University Hospital, De Pintelaan 185,
9000 Ghent, Belgium
bFaculty of Medicine and Health Sciences,
Ghent University, Ghent, Belgium
cFaculty of Healthcare, University College Ghent,
Ghent, Belgium
dDepartment of Microbiology, Ghent University Hospital,
Ghent, Belgiumses. Published by Elsevier Ltd. All rights reserved.
Letter to the Editor / International Journal of Infectious Diseases 14 (2010) e536–e537 e537eDepartment of Health Economy, Interfaculty Centre for
Health Economic Research, Ghent University, Ghent, Belgium
*Corresponding author
E-mail address: stijn.blot@UGent.be (S. Blot)Corresponding Editor: Andy I.M. Hoepelman,
Utrecht, the Netherlands.
6 March 2009
4 June 2009
